Biomaterials for clinical excellence

"The future of biomaterials is in regenerative medicine. Regenerative medicines "helping the body to heal itself" - a fundamentally new approach designed to regenerate naturally lost or damaged tissue without permanent implants for the medical device industry, this represents the needs for new thinking, alongside the new materials. Addressing this problem has been challenged for the last 30 years", says Prof Kohn from New Jersey Center for Biomaterials 2007.1.

Vivoxid's core technologies have been developed to respond this thinking.

The technologies are based on expertise in bioactive and bioresorbable silica- and titanium oxides, and to specific understanding of how these materials and surface technologies react favourably with living tissue. In short, the Vivoxid IPR portfolio is expected to reshape common surgical procedures in the fields of orthopaedics, cranio-maxillofacial and spinal surgeries.

The unique FiberLiveTM resorbable fiber composite technology allows the reinforcement of bioresorbable bone implants, making them load bearing. The technology will make it possible to replace the majority of current metallic implants and to significantly enhance the properties of existing resorbable implants.

 
News:
01.102010
Vivoxid initiates biocompatibility studies for FiberLive technology
Vivoxid has initiated a complete range of biocompatibility studies for the FiberLive technology. Studies are estimated to be completed and reported by the end of Q1 in 2011. The studies will be conducted in accordance with the ISO 10993 standards.        Read more

31.072010
Vivoxid completes the fourth financing round of 1,8 M€
Vivoxid has completed the fourth financing round through which the company raises in total 1,8 M€ of new capital to be used for the next development milestones of the unique FiberLive technology. New financing for the company was completed by the current shareholders of the company and one new undisclosed venture capital investor.  Read more

29.032010
Vivoxid appoints new Quality Assurance Manager
Vivoxid has appointed Ms. Tiina Lehtonen, M.Sc, as Manager of Quality Assurance from 29th of March 2010. Ms. Lehtonen has previously been working in Bayer-Schering Pharma Oy as QA Manager.  Read more



Vivoxid Ltd was granted with the 2009 Millennium Distinct Award.

Technology Academy Foundation in Finland granted the Millennium Distriction Award to Vivoxid on the 9th of January 2009 in recognition of the company's development and commercialization achievements in the fields of innovative applications of new generation biomaterial products.